Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study will test the safety and effectiveness of a combination of pembrolizumab,
olaparib, and temozolomide to see how well these drugs work when given together in people
with a glioma that either did not respond to previous treatment or came back after treatment.